General Information of Drug (ID: DM8RR54)

Drug Name
Yso1 Drug Info
Synonyms
naringenin; 480-41-1; (S)-Naringenin; salipurpol; Salipurol; (S)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; Naringenine; pelargidanon; (2S)-Naringenin; naringetol; Asahina; NARIGENIN; 5,7,4'-Trihydroxyflavanone; NSC 11855; CCRIS 5839; (-)-(2S)-Naringenin; C15H12O5; UNII-HN5425SBF2; NSC 34875; HN5425SBF2; CHEBI:17846; AI3-23355; Flavanone, 4',5,7-trihydroxy-; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; (-)-Naringenin; YSO1; EINECS 207-550-2; NSC-11855; 2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; CHEMBL9352; NARINGENIN, (-)-; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; DTXSID1022392; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-chroman-4-one; (-)-(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (R,S)-Naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; BE-14348A; NSC-34875; (S)-2,3-dihydo-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (S)-; (2R)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; SR-01000721771; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 4',5,7-trihydroxyflavan-4-one; Nari; 2uxu; 4deu; S-Dihydrogenistein; pelargidanon 1602; Spectrum_000247; 4eh3; NARINGENIN [MI]; Spectrum2_000325; Spectrum3_000567; Spectrum4_000124; Spectrum5_001423; NARINGENIN [INCI]; 4',5,7-triOH-Flavone; 4',5,7-Trihydroxyflavanon; SCHEMBL20570; BSPBio_001954; KBioGR_000508; KBioSS_000727; MLS000574861; BIDD:ER0116; DivK1c_000118; SPECTRUM1500746; SPBio_000329; 4',5, 7-Trihydroxyflavanone; DTXCID302392; BDBM23419; HMS500F20; KBio1_000118; KBio2_000727; KBio2_003295; KBio2_005863; KBio3_001454; FTVWIRXFELQLPI-ZDUSSCGKSA-N; NINDS_000118; (2S)-5,7,4'-trihydroxyflavone; AIDS001417; HMS2202M06; (2S)-4',5,7-trihydroxyflavanone; HY-N0100; TNP00287; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; CCG-38601; LMPK12140001; Phytochemistry 8: 127 (1969); s2394; AKOS016843490; CS-6421; DB03467; FS-4072; SDCCGMLS-0066570.P001; (2S)-4',5,7-trihydroxyflavan-4-one; IDI1_000118; NCGC00016457-01; NCGC00016457-02; NCGC00016457-03; NCGC00017346-01; NCGC00163598-01; 1ST40170; AC-33954; CAS-480-41-1; Flavanone, 4',5,7-trihydroxy- (8CI); SMR000156272; FT-0617134; SW219329-1; C00509; EN300-303163; A827427; Q418374; Q-100666; SR-01000721771-3; SR-01000721771-4; BRD-K08832567-001-02-4; BRD-K08832567-001-06-5; 2,3-Dihydro-5,6-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; 13308-00-4
Cross-matching ID
PubChem CID
439246
ChEBI ID
CHEMBL9352
TTD Drug ID
D92IRY

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.38 0.00e+0 34/36 (94.44%) PRIM1;RFC5;POLD2;...
Systemic lupus erythematosus 2.04 5.34e-3 45/135 (33.33%) HLA-DQA1;C1QB;CD40;...
Mismatch repair 2.02 3.56e-3 22/23 (95.65%) RFC5;POLD2;RFC3;...
Ribosome biogenesis in eukaryotes 2.02 2.67e-3 52/108 (48.15%) DKC1;LSG1;DROSHA;...
Cell cycle 1.92 8.54e-3 110/124 (88.71%) SMC1A;PLK1;ESPL1;...
Fanconi anemia pathway 1.91 7.12e-3 36/54 (66.67%) RAD51C;FANCI;RPA3;...
Staphylococcus aureus infection 1.88 6.10e-3 72/95 (75.79%) CFB;HLA-DQA1;C1QB;...
Chemokine signaling pathway 1.85 6.67e-3 163/192 (84.9%) CXCL9;CXCL10;CXCL13;...
VEGF signaling pathway 1.81 1.19e-2 50/59 (84.75%) PLA2G4A;CDC42;PRKCB;...
Homologous recombination 1.78 1.81e-2 35/41 (85.37%) RAD51C;POLD2;RPA3;...
Viral protein interaction with cytokine and cytokine re... 1.77 2.04e-2 84/100 (84%) CXCL9;CXCL10;CXCL13;...
Progesterone-mediated oocyte maturation 1.72 3.29e-2 75/100 (75%) PLK1;CCNB1;CCNA2;...
Influenza A 1.68 4.76e-2 156/172 (90.7%) CXCL10;HLA-DQA1;CCL2;...
Synaptic vesicle cycle -1.73 4.87e-2 63/78 (80.77%) CLTB;SLC6A5;STX3;...
Retinol metabolism -1.79 3.50e-2 41/68 (60.29%) ADH6;UGT2B15;CYP2C18;...
Ascorbate and aldarate metabolism -1.81 4.38e-2 15/30 (50%) ALDH9A1;UGT2B17;ALDH2;...
Cardiac muscle contraction -1.83 4.91e-2 64/87 (73.56%) SLC9A7;COX7A2L;MYH7;...
Pentose and glucuronate interconversions -1.92 4.61e-3 17/34 (50%) UGT2B17;UGT2B15;AKR1B10;...
Metabolism of xenobiotics by cytochrome P450 -1.95 0.00e+0 49/77 (63.64%) UGT2B17;GSTT2;CBR1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H